Literature DB >> 20947804

Clinicopathological characteristics of triple-negative invasive mammary carcinomas in African-American versus Caucasian women.

Ossama Tawfik1, Keisha Davis, Bruce F Kimler, Marilyn K Davis, Stephanie Hull, Fang Fan, Qamar J Khan, Anne P O'Dea, Patricia Thomas.   

Abstract

African-American (AA) women are more likely to have late stage, aggressive, rapidly growing, and less hormone-responsive breast tumors. An aggressive subtype of cancer, known as "Triple-Negative" (TN), that is negative for Her-2 and for estrogen and progesterone receptors (ER and PR), is reported to be more common in AA women. We examined the clinical, histopathologic, and prognostic features of TN tumors in AA and Caucasian women. Tumor size, grade, histologic type, lymphovascular invasion (LVI), lymph node status, patient survival, ploidy status, and expression of ER, PR, p53, epidermal growth factor receptor (EGFR), MIB-1, Bcl-2, Her-2, p27, and p21 were evaluated. The TN tumors (75%) were high grade, large, aneuploid tumors that occurred in younger women and were more likely to have a high rate of LVI, elevated MIB-1 score, and nodal metastases. Patients with TN tumors showed poorer overall survival. There was no difference in overall or disease-free survival (p = 0.46) in the AA versus Caucasian women. LVI was a significant predictor of overall survival in AA but not in Caucasian women. There were minor differences in histopathologic features, biomarker expressions, and survival in AA and Caucasian women with TN tumors. The absence of LVI in AA patients predicted an excellent probability of survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20947804

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  8 in total

1.  High motility of triple-negative breast cancer cells is due to repression of plakoglobin gene by metastasis modulator protein SLUG.

Authors:  Charvann K Bailey; Mukul K Mittal; Smita Misra; Gautam Chaudhuri
Journal:  J Biol Chem       Date:  2012-04-11       Impact factor: 5.157

2.  Outcome of triple-negative breast cancer in patients with or without markers regulating cell cycle and cell death.

Authors:  Dong Won Ryu; Chung Han Lee
Journal:  J Korean Surg Soc       Date:  2012-09-25

3.  Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis.

Authors:  Mohammed S Fayaz; Mustafa S El-Sherify; Amany El-Basmy; Sadeq A Zlouf; Nashwa Nazmy; Thomas George; Susan Samir; Gerges Attia; Heba Eissa
Journal:  Rep Pract Oncol Radiother       Date:  2013-09-26

4.  Relative and disease-free survival for breast cancer in relation to subtype: a population-based study.

Authors:  Pamela Minicozzi; Francesca Bella; Angela Toss; Adriano Giacomin; Mario Fusco; Maurizio Zarcone; Rosario Tumino; Fabio Falcini; Rosaria Cesaraccio; Giuseppa Candela; Francesco La Rosa; Massimo Federico; Milena Sant
Journal:  J Cancer Res Clin Oncol       Date:  2013-07-28       Impact factor: 4.553

Review 5.  Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis.

Authors:  Li Zhang; Cheng Fang; Xianqun Xu; Anling Li; Qing Cai; Xinghua Long
Journal:  Biomed Res Int       Date:  2015-01-28       Impact factor: 3.411

6.  Race is not a factor in overall survival in patients with triple negative breast cancer: a retrospective review.

Authors:  Athena Starlard-Davenport; Katherine Glover-Collins; Issam Mahkoul; Laura Hutchins; Kent Westbrook; Soheila Korourian; Kimberly Enoch; Michael Preston; Shakia N Jackson; V Suzanne Klimberg; Ronda Henry-Tillman
Journal:  Springerplus       Date:  2013-10-07

7.  Clinicopathological factors associated with novel prognostic markers for patients with triple negative breast cancer.

Authors:  Anna M Badowska-Kozakiewicz; Michał P Budzik; Anna Liszcz; Maciej T Sobieraj; Aleksandra I Czerw; Maria Sobol; Janusz Patera; Andrzej Deptała
Journal:  Arch Med Sci       Date:  2018-11-13       Impact factor: 3.318

8.  Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity.

Authors:  Melissa B Davis; Xinyu Liu; Shiyao Wang; Jaxk Reeves; Andrey Khramtsov; Dezheng Huo; Olufunmilayo I Olopade
Journal:  Mol Cancer       Date:  2013-05-10       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.